Voltar
Artigo Revisado por pares
BIBTEX RIS

Buspirone augmentation of fluoxetine in obsessive-compulsive disorder

1990; American Psychiatric Association; Volume: 147; Issue: 6 Linguagem: Inglês

10.1176/ajp.147.6.798

ISSN

1535-7228

Autores

Paul J. Markovitz, Susan J. Stagno, Joseph R. Calabrese,

Tópico(s)

Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Resumo

Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1a receptor in obsessive-compulsive disorder.

Referência(s)